Anti-Psoriatic Activity of Clitoria ternatea in Animal Model of Psoriasis
Aasiya N. Shaikh*, Anjali M. Wankhade, Vivek V. Paithankar, Jugulkishor V. Vyas
Department of Pharmacology, Vidyabharti College of Pharmacy, Amravati 444601 Maharashtra India.
*Corresponding Author E-mail: aasiyashaikh9156@gmail.com
ABSTRACT:
Psoriasis is a multifactorial inflammatory skin disorder characterized by abnormal epidermal proliferation, erythema, scaling, and skin thickening. Conventional therapeutic approaches are available for its management; however, prolonged treatment may cause undesirable side effects. Consequently, increasing attention has been directed toward the development of herbal formulations as safer alternatives. The present investigation was designed to formulate topical creams incorporating ethanolic flower extract of Clitoria ternatea at concentrations of 10% and 20% (w/w) and to assess their anti-psoriatic activity. The developed formulations were examined for various quality attributes, including appearance, pH, viscosity, homogeneity, spreadability, extrudability, and storage stability. UV-visible spectrophotometry was employed to analyze the extract. Anti-psoriatic efficacy was evaluated using an imiquimod-induced psoriasis-like mouse model for 14 days. Disease severity was determined by monitoring erythema, scaling, skin thickness, PASI score, and body weight changes throughout the experimental period. Both formulations showed desirable physicochemical characteristics and maintained their stability during storage. Application of the extract-containing creams resulted in a noticeable improvement in psoriatic symptoms compared with untreated diseased animals. The cream containing 20% extract exhibited superior activity when compared with the 10% formulation. Overall, the findings suggest that Clitoria ternatea flower extract possesses promising anti-psoriatic potential and may serve as an effective herbal topical therapy for psoriasis.
KEYWORDS: Clitoria ternatea, psoriasis, Herbal topical formulation, Ethanolic extract, Imiquimod-induced model, Antipsoriatic activity.
INTRODUCTION:
Psoriasis is a long-term immune-associated dermatological disorder characterized by abnormal growth of epidermal cells and persistent skin inflammation.1,2,3 Psoriasis is a chronic immune-mediated inflammatory skin disease affecting about 2–3% of the global population.
It can occur at any age, most commonly between 15 and 30 years, and affects males and females equally.4,5 The condition typically manifests as well-demarcated erythematous lesions covered with whitish scales and frequently affects the scalp, elbows, knees, and lumbosacral region. The disease strongly affects patients physical, psychological, and social health, significantly lowering quality of life.6,7 It is broadly classified into five major clinical forms plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, and erythrodermic psoriasis. These subtypes differ in their clinical appearance, anatomical distribution, severity, and disease progression. Among them, plaque psoriasis is the most prevalent form and represents the majority of reported cases.8,9
The onset of psoriasis results from a complex interaction between genetic predisposition and external triggering factors, including microbial infections, emotional stress, and cutaneous trauma. These stimuli initiate immune responses involving dendritic cells and T-cells, leading to the secretion of inflammatory mediators that contribute to disease progression.10,11,12 Although its exact cause remains unclear, the disease is believed to result from an interaction between genetic susceptibility, immune dysfunction, and environmental factors. In genetically predisposed individuals, abnormal activation of T lymphocytes and the excessive production of inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-17(IL-17), and interleukin-23(IL-23), promote rapid keratinocyte proliferation and chronic skin inflammation. Several environmental factors, such as infections, physical trauma to the skin, psychological stress, smoking, alcohol consumption, obesity, and certain medications, may trigger the onset or exacerbate existing psoriasis.13,14 Psoriasis is also commonly associated with comorbidities including psoriatic arthritis, cardiovascular disease, metabolic disorders, and psychological conditions.15,16,17
Despite the availability of multiple therapeutic strategies, their prolonged administration may be associated with safety concerns, economic burden, and inconsistent clinical effectiveness. This has increased interest in plant-based therapies as safer alternatives. Clitoria ternatea L. (Family: Fabaceae), or butterfly pea, contains bioactive compounds such as flavonoids, anthocyanins, tannins, and phenolics, which show antioxidant and anti-inflammatory activity potentially useful for psoriasis treatment.18,19,20 Clitoria ternatea has been traditionally valued for its medicinal importance and is commonly used in herbal practices. It is known for its potential to support brain function and improve memory. The plant has also been used for managing conditions such as fever, inflammation, pain, and diabetes. Various studies suggest that it contains beneficial biological properties, including antioxidant, anti-inflammatory, antimicrobial, antidiabetic, and liver-protective effects, making it a significant medicinal herb.21,22 Previous research has demonstrated the anti-inflammatory effects of Clitoria ternatea, supporting its potential role in managing inflammatory skin disorders. Therefore, this study was undertaken to formulate and evaluate a topical cream containing Ethanolic flower extract of Clitoria ternatea and to assess its anti-psoriatic activity in an experimental model.
2. MATERIALS AND METHODS:
2.1. Collection and Authentication:
Flowers of Clitoria ternatea were collected from different locations in Amravati, Maharashtra, India. The plant material was identified and authenticated by Mrs. L. P. Khalid, Assistant Professor, Department of Botany, Vidyabharti Mahavidyalaya, Amravati. The authenticated plant material was subsequently used for the experimental study.
2.2. Extraction Process:
The flowers of Clitoria ternatea were collected and cleaned thoroughly with distilled water to eliminate adhering contaminants. After washing, the flowers were dried under shade at ambient temperature until complete moisture removal was achieved. The dried material was then reduced to a coarse powder using a mechanical grinder. Extraction was carried out by macerating the powdered material in ethanol for 72h, with periodic agitation to enhance the release of bioactive constituents into the solvent. After maceration, the extract mixture was passed through Whatman No. 1 filter paper to separate the solid plant material from the liquid extract. The obtained filtrate was concentrated by removing the solvent through evaporation, yielding a semisolid extract. This semisolid mass was further dried to obtain the crude ethanolic extract. The final extract was transferred to an airtight container and stored under suitable conditions until required for subsequent analytical and formulation studies.23,24
2.3. Preliminary Phytochemical Screening:
Preliminary phytochemical analysis of the ethanolic flower extract of Clitoria ternatea was carried out using established qualitative methods. The extract was screened for different classes of secondary metabolites, including alkaloids, flavonoids, glycosides, tannins, phenolics, saponins, and terpenoids. Identification of these phytochemicals was based on specific visual observations, such as changes in coloration and the formation of precipitates during the analysis.25,26
2.4. Formulation of Cream:
An oil-in-water cream was formulated by employing the fusion method. Initially, stearic acid, cetostearyl alcohol, and liquid paraffin were combined and heated to 70–75°C to form a uniform oil phase. Simultaneously, the aqueous phase was prepared by dissolving methyl paraben in distilled water, followed by the incorporation of glycerin. Both phases were maintained at the same temperature prior to emulsification. Triethanolamine was added to the aqueous phase with gentle stirring. The heated oil phase was then slowly incorporated into the aqueous phase under continuous stirring to facilitate the formation of a stable emulsion. Mixing was continued until a smooth and consistent cream base was obtained. The resulting emulsion was homogenized to enhance uniformity and physical stability. As the formulation cooled, ethanolic flower extract of Clitoria ternatea (10% and 20%) was gradually incorporated with constant stirring to ensure even distribution of the extract throughout the cream matrix. When the temperature reached below 40°C, fragrance was added and mixed thoroughly. The final volume was adjusted using distilled water, and the prepared formulations were filled into suitable containers and stored under appropriate conditions until further evaluation.27
Table no: 1 Formulation of Herbal Cream
|
Ingredients |
10% EECT Cream |
20% EECT Cream |
|
EECT Extract |
5gm |
10g |
|
Stearic Acid |
4gm |
4gm |
|
Cetosteryl Alcohol |
1gm |
1gm |
|
Liquid Paraffin |
1gm |
1gm |
|
Glycerin |
5gm |
5gm |
|
Methyl Paraben |
0.09gm |
0.09gm |
|
Triethanolamine |
1gm |
1gm |
|
Oleum rose oil |
0.25gm |
0.25gm |
|
Distilled water |
q.s |
q.s |
2.5. Evaluation of Herbal Cream:
The formulated herbal cream was systematically evaluated for its physicochemical properties and performance characteristics using established analytical methods. The cream was assessed for physical and pharmaceutical attributes, including appearance, uniformity, pH, spreadability, viscosity, washability, extrudability, UV absorbance, and stability. These evaluations were conducted to determine the quality, performance, and suitability of the formulation for topical application.28,29
2.6. Experimental Animals:
Swiss albino mice were procured from the Department of Pharmacology, Vidyabharti College of Pharmacy, Amravati (CPCSEA Registration No. 1504/PO/RE/11/CPCSEA). The experimental protocol was approved by the Institutional Animal Ethics Committee (IAEC), and all procedures were carried out in accordance with CPCSEA regulations. Animals were housed under controlled environmental conditions, including a temperature of 25±1°C, relative humidity of 50–55%, and a 12h light/dark cycle. Standard pellet feed and drinking water were provided ad libitum throughout the study. Prior to initiation of the experiment, the animals were acclimatized to the laboratory environment for a period of seven days to ensure physiological adaptation and minimize stress-related variations.30,31
2.7. Induction of Psoriasis:
Psoriasis-like skin inflammation was established in Swiss albino mice through the topical administration of 62.5mg of 5% imiquimod cream on a shaved dorsal region (2 × 3cm) for seven successive days. Continuous exposure to IMQ resulted in typical psoriatic manifestations, including erythema, scaling, and increased skin thickness. After disease induction, animals were treated with either Clobetasol propionate (0.05%) or EECT cream (10% and 20%) from Day 8 to Day 14. The therapeutic effect was assessed by PASI scoring and histopathological evaluation of skin tissues.32,33
2.8. Treatment Protocol:
Table no 2 : Treatment Protocol
|
Sr. No. |
group |
No. of animals |
Treatment and route of administration |
|
1. |
I (control) |
6 |
Simple base cream (Topical) |
|
2. |
II (IMQ induced) |
6 |
Imiquimod cream 5% (Topical) |
|
3. |
III (Standard) |
6 |
Clobetasol propionate 0.05% (Topical) |
|
4. |
IV (EECT) |
6 |
EECT Cream 10% (Topical) |
|
5. |
V (EECT) |
6 |
EECT Cream 20% (Topical) |
2.9. Evaluation of Antipsoriatic Activity:
The antipsoriatic potential of the formulated Clitoria ternatea extract cream was evaluated in IMQ-induced psoriatic mice. Assessment was carried out through both clinical observations and histopathological studies. Parameters including erythema, scaling, skin thickness, PASI score, body weight, and microscopic skin changes were recorded to determine treatment efficacy.
Clinical Evaluation:
Clinical observations were performed at predetermined intervals to monitor disease progression and therapeutic response. Body weight, skin thickness, and PASI scores were measured throughout the experimental period.
Histopathological Evaluation:
At the completion of the study, skin tissues were collected and preserved in formalin for histological examination. Processed tissue sections were stained with Hematoxylin and Eosin (H&E) and examined microscopically for epidermal hyperplasia, inflammatory cell infiltration, and other pathological alterations associated with psoriasis.
2.10. Statistical Analysis:
All data were expressed as mean±SEM (n = 6). Statistical analysis was performed using two-way ANOVA followed by Tukey's multiple comparison test. Values with p<0.001 compared to the IMQ control group were considered statistically significant.
RESULT:
Table no 3: Phytochemical Analysis of Ethanolic Extract of Clitoria ternatea
|
Sr. No |
Chemical constituents |
Name of the test |
Result |
|
1. |
Alkaloids |
Dragendroff Test, Wagner’s Test |
+ |
|
2. |
Flavonoids |
Shinoda Test, Alkaline Reagent Test |
+ |
|
3. |
Glycosides |
Keller Kianni Test, Liebermanns Tes |
+ |
|
4. |
Saponins |
Foam Test |
+ |
|
5. |
Terpenoids |
Copper Acetate Test |
+ |
|
6. |
Tannins |
Ferric Chloride Test |
+ |
|
7. |
Steroids |
Salwkowski Test |
+ |
|
8. |
Phenolic compounds |
Gelatin Test, Lead Acetate Test |
+ |
|
9. |
Anthocyanin’s |
NaOH Test |
+ |
|
10. |
Carbohydrates |
Molisch's test |
- |
|
11. |
Protein and amino acids |
Biuret Test, Ninhydrin test |
- |
Table no 4: Physicochemical Evaluation of EECT Cream
|
Sr. No |
Evaluation parameters |
Result of Clitoria Ternatea cream (10%) |
Result of Clitoria Ternatea cream (20%) |
|
1. |
Organoleptic properties |
Light brown colour, smooth, homogeneous, pleasant mild herbal odour |
Dark brown colour, smooth, homogeneous, pleasant mild herbal odour |
|
2. |
pH |
6.4 indicating suitability for skin application |
6.5 indicating good compatibility for skin |
|
3. |
Viscosity |
Showed viscosity for easy topical application |
Optimum viscosity, suitable for topical use |
|
4. |
Spreadability |
Good spreadability, easily spreads on skin |
Showed excellent spreadability and smooth application |
|
5. |
Extrudability |
Easily extruded from tube with slight pressure |
Cream showed good extrudability with slight pressure |
|
6. |
Homogeneity |
Uniform, no lumps |
Uniform, no lumps or phase separation |
|
7. |
Washability |
Easily removal with water |
Easily washable after application |
|
8. |
Stability |
Formulation was stable at room temperature and showed no change in colour, odour, pH, or phase separation during storage period |
Formulation was stable at room temperature and showed no change in colour, odour, pH, or phase separation during storage period |
|
9. |
Skin irritation test |
No redness, swelling or irritation observed |
No redness, swelling or irritation observed |
|
10. |
UV Visible spectroscopy |
10% EECT cream showed an absorbance value of 1.71 at 320 nm. |
20% EECT cream exhibited a higher absorbance value of 2.22 at the same wavelength. |
Evaluation of Antipsoriatic Activity:
1. Body Weight
Figure 1. Effect of topical EECT formulations on body weight during IMQ-induced psoriasis in mice.
Data are expressed as mean± SEM (n = 6). Statistical analysis was performed using Two-way ANOVA followed by Tukey's multiple comparison test. Statistical significance was considered at p<0.001.
Body weight declined in the IMQ-treated group over the study period. Topical treatment with clobetasol propionate (0.05%), EECT 10%, and EECT 20% attenuated this weight loss compared with the IMQ group. The greatest recovery in body weight was seen with EECT 20%, suggesting a beneficial effect of the formulation.
2. Clinical Evaluation of Psoriasis Severity Parameters
A) B)
C) D)
Figure 2. Figure 2. Effect of EECT Cream on Erythema, Scaling, Skin Thickness, and PASI Score in IMQ-Induced Psoriasis Mice. Data are presented as mean±SEM (n = 6). Two-way ANOVA with Tukey’s multiple comparisons test was used for statistical analysis. *p < 0.001 versus the IMQ-induced control.
IMQ (5%) treatment produced progressive increases in erythema, scaling, skin thickness, and overall PASI score, confirming induction of psoriasiform lesions. Topical clobetasol propionate (0.05%) significantly reduced all clinical parameters. EECT cream at 10% and 20% also improved erythema, scaling, skin thickness, and PASI score compared with the IMQ group, with the 20% formulation showing greater efficacy than the 10% cream. These findings indicate a dose‑dependent antipsoriatic effect of the EECT formulation.
Histopathology:
Figure no 3: Histopathological Evaluation of EECT Cream in Psoriasis Mice Model A) Normal control, B) IMQ Induced (5%), C) Clobetasol propionate (0.05%), D) EECT Cream (10%), E) EECT Cream (20%)
Microscopic analysis of skin sections from control mice showed intact epidermal structure without significant inflammatory cell infiltration. In contrast, IMQ-treated animals developed psoriasiform alterations, including pronounced epidermal thickening, acanthosis, and heavy inflammatory cell infiltration. Topical clobetasol propionate (0.05%) markedly reduced these pathological changes and largely restored normal skin architecture. EECT cream at both 10% and 20% concentrations also improved histological outcomes by decreasing epidermal hyperplasia and inflammatory infiltration compared with the IMQ group. The 20% EECT formulation produced a greater degree of histological improvement than the 10% formulation, indicating dose-related protective effects against IMQ-induced psoriasiform lesions.
DISCUSSION:
The imiquimod-induced psoriasis model effectively produced characteristic psoriasis-like manifestations, including erythema, scaling, increased skin thickness, and epidermal hyperplasia. In the present study, the antipsoriatic potential of a cream formulated with ethanolic extract of Clitoria ternatea flowers was evaluated using this experimental model. Phytochemical screening of the extract revealed the presence of flavonoids, tannins, terpenoids, saponins, and phenolic compounds, which are known to possess anti-inflammatory and antioxidant activities. Topical treatment with EECT cream significantly improved psoriasis-associated symptoms compared with the disease control group. A marked reduction in erythema, scaling, skin thickness, and PASI score was observed in treated animals. Histopathological examination further confirmed the therapeutic effect of the formulation by demonstrating reduced epidermal hyperplasia and inflammatory cell infiltration. The observed findings are in agreement with previous studies reporting the anti-inflammatory and protective effects of Clitoria ternatea and its bioactive constituents.
Among the tested formulations, the 20% EECT cream produced greater improvement than the 10% formulation, indicating enhanced efficacy at a higher concentration. The beneficial effects may be attributed to the synergistic action of phytoconstituents present in the extract, which could modulate inflammatory pathways involved in psoriasis. Overall, the results suggest that Clitoria ternatea flower extract possesses promising antipsoriatic activity and may serve as a potential natural therapeutic agent for the management of psoriasis. Further studies are required to elucidate its exact mechanism of action and establish its long-term safety and efficacy. The observed findings are consistent with previous reports demonstrating the anti-inflammatory and antioxidant properties of Clitoria ternatea flower extract. The reduction in epidermal hyperplasia and inflammatory infiltration may be attributed to these bioactive constituents.
CONCLUSION:
The present study showed that a topical cream containing an ethanolic extract of Clitoria ternatea flowers exerted significant antipsoriatic effects in the imiquimod-induced mouse model. Topical treatment markedly reduced erythema, scaling, and skin thickening, and lowered overall disease severity. Histopathological evaluation demonstrated improved skin architecture with decreased epidermal proliferation and reduced inflammatory cell infiltration. The 20% EECT formulation produced greater therapeutic benefit than the 10% formulation. These effects are likely attributable to the plant’s bioactive constituents with antioxidant and anti‑inflammatory properties. While results are promising, further investigations are required to confirm efficacy and elucidate the underlying mechanisms.
REFERENCES:
1. N. Sondhi S, Jindal S, Pandit V, Ashawat MS. Treatment and management for patients with mild to severe psoriasis: a review. J Clin Aesthet Dermatol. 2023; 16(1): 45-52.
2. Ingawale R, Adsul AV, Chavan P, Kale G. Protecting Psoriasis: A Comprehensive Review of Sunscreen. J Pharm Res. 2024; 12(3): 45-60.
3. Unissa R, Kumar PM, Sunil G. Psoriasis: A Comprehensive Review. J Pharm Sci. 2024; 15(2): 123-145.
4. Tripathi KD. Essentials of Medical Pharmacology. 9th ed. New Delhi: Jaypee Brothers Medical Publishers; 2024.
5. Sharma MC, Sharma M. Novel applications of Cold Atmospheric Plasma for the treatment of Plaque Psoriasis. J Pharm Sci Tech. 2025; 18(4): 78-92.
6. Vijayalakshmi A, Srinivas P, Vinodh MN, Gaffur A, Singh UK. Antimicrobial activity of antipsoriatic plant Givotia rottleriformis Griff. Ex Wight. Res J Pharm Technol. 2016; 9(8): 1109-1114.
7. Kakade KV, Khaire RD. A review on psoriasis. Int J Technol. 2022 Jul–Dec; 12(2): 47–50.
8. Singh N, Sondhi S, Jindal S, Pandit V, Ashawat MS. Treatment and management for patients with mild to severe psoriasis: A review. Asian J Pharm Res. 2020;10(4):286-292.
9. Sharma S, Sharma R, Goyal K, Jindal S. Potential of herbal treatment of psoriasis: A laconic review. Asian J Res Pharm Sci. 2021;11(1):51-57.
10. Gangwar RS, Gudjonsson JE, Ward NL. Mouse models of psoriasis – A comprehensive review. J Invest Dermatol. 2021; 142(3 Pt B): 884–897.
11. Lin YK, Yang SH. Topical clobetasol propionate in psoriasis: efficacy and safety evaluation in clinical practice. Dermatol Ther. 2015; 28(4): 221-228.
12. Sarafian, G., Afshar, M. et.al. Topical turmeric microemulgel in the management of plaque psoriasis: A clinical evaluation. Iranian Journal of Pharmaceutical Research: IJPR. 2015; 14(3): 865-876.
13. Dhiman K, Sharma A, Sharma A, Goyal K, Pandit V, Ashawat MS, et al. Application of berberine on skin diseases: A review. Res J Pharm Dos Forms Technol. 2022; 14(4): 304-308.
14. Bhadane A, Mankar SD. A review on nanofiber for topical drug delivery of therapeutic skin disorder. Asian J Res Pharm Sci. 2023; 13(4): 338–345.
15. Mehta NN, Azfar RS, Shin DB, Neimann AL, et.al, Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study. JAMA. 2010; 303(17): 1735–41.
16. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol.2017; 76(3): 377–90.
17. Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–94.
18. Kiranmai VS, Kumar PK, Rajesham VV, Rao TR. Extraction Methods and Pharmacological Importance of Clitoria ternatea Plant. Int J Pharm Sci Rev Res. 2023Nov-Dec; 83(2): 99–105.
19. D. Sai Koteswar Sarma, Deepak Kumar, Yamini C, et.al, Review on Clitoria ternatea. Int J Pharm Sci Med. 2023; 8(9): 43–58.
20. Ali Esmail Al-Snafi A. Pharmacological importance of Clitoria ternatea – A review IOSR J Pharm. 2016; 6(3): 68–83.
21. Drisya MK, Sherikum S. GC–MS analysis of ethyl acetate extract leaves of Clitoria ternatea Linn. Asian J Pharm Anal. 2022 Mar; 12(1): 1–4.
22. Rangasamy P, Hansiya VS, Maheswari PU, Suman T, Geetha N. Phytochemical analysis and evaluation of in vitro antioxidant and anti-urolithiatic potential of various fractions of Clitoria ternatea L. blue flowered leaves. Asian J Pharm Anal. 2019; 9(2): 67–76.
23. Swathi KP, Jayaram S, Sugumar D, Rymbai E. Evaluation of antiinflammatory and anti- arthritic property of ethanolic extract of Clitoria ternatea. Chin Herb Med. 2020 Dec 1; 13(2): 243-249.
24. Marpaung AM, Andarwulan N, et. Al, Thermal degradation of anthocyanins in butterfly pea flower extract. Food Chem. 2019; 275: 437-445.
25. Jeyaraj EJ, Lim YY, et. al, Extraction methods of butterfly pea (Clitoria ternatea) flower and biological activities of its phytochemicals. J Food Sci Technol. 2021; 58(6): 2054-2067
26. Mukherjee PK. Quality control of herbal drugs: an approach to evaluation of botanicals. New Delhi: Business Horizons; 2002
27. Kokate CK, Purohit AP, Gokhale SB. Pharmacognosy. 49th ed. Pune: Nirali Prakashan; 2014.
28. Ashawat MS, Saraf S, Saraf S. Preparation and characterization of herbal creams for improvement of skin viscoelastic properties. Int J Cosmet Sci. 2008; 30(3): 183-193.
29. Mithal BM. A handbook of cosmetics. 2nd ed. Mumbai: Vallabh Prakashan; 2005.
30. Kadam PV, Bhingare CL, et.al, Development and validation of UV spectrophotometric method for the estimation of curcumin in cream formulation. Pharm Methods. 2013; 4(2): 43-45.
31. Yadav AR. CPCSEA guidelines for laboratory animal facility. Int J Pharmacols Clin Res. 2020; 2(1): 9-13.
32. Van der Fits L, Mourits S, Voerman JSA, Kant M, Boon L, Laman JD, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009; 182(9): 5836–45.
33. Alsahli TG, Alharbi KS, Alenezi SK, ALQahtani R, Afzal M, Kazmi I, et al. Aloesin alleviates imiquimod-induced psoriasis in dermal layers through inhibition of interleukins and NF-κB signaling pathways. Sci Rep. 2026; 16: 337.
|
Received on 27.06.2026 Revised on 05.08.2026 Accepted on 07.09.2026 Published on 17.10.2026 Available online from October 28, 2026 Res.J. Pharmacology and Pharmacodynamics.2026;18(4):373-378. DOI: 10.52711/2321-5836.2026.00050 ©A and V Publications All right reserved
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|